CClinicalTrials.gg
CompletedNCT03546023Updated Sep 11, 2019

Brief Pain Inventory to Assess Cancer Pain and Quality of Life

An observational study in Chronic Cancer Pain, sponsored by Tata Memorial Hospital. Completed at 2 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-11.

Sponsored by Tata Memorial Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
900
Ages
18 Years and older
Sex
All
01

Study summary

Cancer-related pain has a major adverse impact on functional status and quality of life. Recently, a Survey conducted in 2015 in 10 Asian countries showed that among cancer patients in Asian population, 86% of patients reported that their pain affected their activities of daily living, 87% their sleep, 92% their concentration and focus, and 67% excessive reliance on others. Only 34% reported a good quality of life. Effective pain management may help the patient to focus on the positive aspects of life, decreasing the focus on pain and also promote better adherence to reasonable treatment plans. Hence the emphasis is on improving the Quality of Life and not mere pain control.

Read the detailed description

This is a Prospective Observational Study. All new patients in chronic pain OPD are been administered BPI questionnaire as a standard of practice in our institute, in the language best understood by them e.g. English, Hindi, Marathi, Bengali. The participants will be asked to complete it once during their first visit to the pain clinic, before the start of treatment or ongoing treatment for pain (Baseline) and then during subsequent visits (Follow up). Most chronic pain patients are advised to follow-up by one to two weeks. Patients who are willing to participate in the study will be included after obtaining an informed consent. Data will be collected from BPI, Chronic Pain Record form and EMR and will be analyzed. Demographic data, diagnosis, pain data sheet, drug treatment as well as other form of therapies will be recorded. There will be no direct communication with the patient and data of quality of life will be retrieved from pain clinic records.

The Brief Pain Inventory (BPI) long form and short form questionnaire is a validated multidimensional pain assessment tool developed by Cleeland and Ryan. It is one of the most commonly used measures for assessing both pain severity and interference with functions in adults with cancer, thereby satisfying two recommendations (assessment of pain to include both intensity and interference) set by the Initiative on Methods, Measurements, and Pain Assessment in Clinical Trials (IMMPACT) group. It is brief, self administered, easily understood and can be administered to large numbers of patients,.

It contains three questions regarding pain intensity and seven regarding pain interference that are rated on an ordinal numerical scale with anchors of 0 (no pain/interference) to 10 (maximum pain/interference). Pain intensity is measured according to the worst pain experienced in the last three days, average pain in the last three days, and current pain. Pain interference assesses how that pain has affected general activity, mood, walking ability, normal work, relations with others, sleep, and enjoyment of life. The sum of the scores of the pain intensity items represents the summed pain intensity score and the sum of the scores on the pain interference items represents the summed interference score. In addition, the patient enters his pain localization on a body drawing and can give details of his current medication.

02

Conditions studied

  • Chronic Cancer Pain

Browse trials for

Keywords

  • Chronic cancer pain
  • pain clinic
  • Brief Pain Inventory
03

In context

Cancer Pain

338 studies on the registry are indexed under Cancer Pain; 71 are open to participants now.

This study's enrollment of 900 is above the median of 140 across 68 observational studies indexed under Cancer Pain.

Browse Cancer Pain studies →

Lead sponsor

Tata Memorial Hospital is the lead sponsor of 97 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients attending the Pain Clinic over a period of 12 months aged 18 years and more.

Inclusion criteria

  • All patients registered in chronic pain OPD for 12 months from the date of approval of the study by IEC, at Tata Memorial Hospital.
  • Age ≥ 18 years

Exclusion criteria

Exclusion Criteria:

  • Incomplete BPI forms.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
900 participants (actual)
Patient registry
No

Interventions

  • OtherPatient Interview

    BPI scores will be asked by the Doctor or the Research Nurse

06

What researchers measure

Primary outcomes

  1. Functional activity measurement using the Brief Pain Inventory (BPI)

    Any change in baseline score of functional activity from BPI during the followup visit.

    Time frame: followup visit (minimum 7 days)

07

Study locations

2 sites
  • Tata Memorial Centre
    Mumbai, Maharashtra 400010, India
  • Tata Memorial Centre
    Mumbai, Maharashtra 400025, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03546023
Lead sponsor
Tata Memorial Hospital
Responsible party
Raghu Thota (Professor, Tata Memorial Hospital) — Principal investigator
First posted
Jun 6, 2018
Start date
Jun 5, 2018
Primary completion
Jun 4, 2019
Completion
Jun 4, 2019
Last update
Sep 11, 2019

Study contacts

Raghu Thota, MD, MNAMS
principal investigator · Tata Memorial Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion